Galeterone companion diagnostic

Drug Profile

Galeterone companion diagnostic

Alternative Names: AR-V7 companion diagnostic

Latest Information Update: 01 Jul 2015

Price : $50

At a glance

  • Originator Tokai Pharmaceuticals
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 24 Jun 2015 Phase-III clinical trials in Prostate cancer (Diagnosis) in USA (unspecified route)
  • 15 Jan 2015 Galeterone companion diagnostic is available for licensing as of 15 Jan 2015.
  • 12 Jan 2015 Clinical trials in Prostate cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top